When I ask it about city oh hope trial. I get this response. Now it mostly cites reddit because where else is info currently available. One off stand alone queries dont work well.Now I'm not sure if the 96% of oncology drug approvals the last 5 years have gone through syneos is true or not. But I bet they are doing something rightPs. Here's a page on Syneos site that includes a section on ai etc. Maybe it's all marketing bs but I think you err in comparing what we are doing vs syneos.
https://www.syneoshealth.com/
"Tell me about the CHAMP trial at City of hope"
Ai
"The CHAMP trial at City of Hope is a highly anticipated, Investigator-Initiated Trial (IIT) led by Dr. Pashtoon Kasi. It evaluates an innovative treatment strategy for patients with advanced colorectal cancer (CRC) metastatic to the liver.
The trial officially received institutional scientific committee and IRB approvals and has been moving through its regulatory steps for clearance.
1. The Core Trial Design
The CHAMP study utilizes a direct, organ-targeted delivery method designed to attack aggressive liver lesions while simultaneously shielding healthy tissue:
* The Therapeutics: The trial combines 700 mg of leronlimab with 4 months of standard regional Hepatic Artery Infusion Pump (HAIP) chemotherapy.
* The Patient Cohort: The study plans to enroll approximately 36 patients.
* No Pre-Screening Barrier: Crucially, CCR5 positivity is not a gating criterion for patient enrollment. Because the drug is acting broadly on the tissue architecture and protective microenvironment, patients do not need to test positive for a narrow biomarker upfront to qualify.
2. The Dual-Action Endpoints
What makes the CHAMP trial structurally unique is its primary endpoint, which shifts focus to how a therapeutic platform protects an entire organ system:
* The Primary Endpoint (Liver Protection): The trial features a liver biopsy endpoint specifically to assess fibrosis prevention. Chemotherapy delivered directly to the liver via an infusion pump is highly cytotoxic and notorious for causing severe biliary sclerosis and hepatic scarring (fibrosis). By utilizing 700 mg of leronlimab, the trial aims to block the chronic CCL5/CCR5 inflammatory feedback loop that commands hepatic stellate cells to lay down scar tissue.
* The Secondary Endpoint (Anti-Tumor Activity): Alongside organ protection, the study will measure direct radiographic and molecular tumor regression within the liver.
3. Why the 700 mg Dose Matters for the CHAMP Model
By utilizing the higher 700 mg dose, the CHAMP protocol ensures absolute, sustained receptor occupancy directly within the highly dense hepatic environment.
As we mapped out through the Bellomo (THBS1-SPP1 axis) and Qijie Zhao (mechanobiology) frameworks, the liver is the primary geographic battleground where monocytes transform into scar-building, immune-excluding SPP1+ core macrophages. Scurrying through the liver via their CCR5 actin-myosin motors, these cells typically turn chemotherapy-induced cell death into rigid fibrous tissue.
The CHAMP trial is designed to test if leronlimab can enforce mechanical paralysis on these macrophages—preventing both the toxic, pump-induced liver fibrosis and the tumor’s ability to build a defensive structural wall. This allows the high-concentration pump chemotherapy to cleanly destroy the malignant core without destroying the architecture of the liver itself".
https://www.syneoshealth.com/
"Tell me about the CHAMP trial at City of hope"
Ai
"The CHAMP trial at City of Hope is a highly anticipated, Investigator-Initiated Trial (IIT) led by Dr. Pashtoon Kasi. It evaluates an innovative treatment strategy for patients with advanced colorectal cancer (CRC) metastatic to the liver.
The trial officially received institutional scientific committee and IRB approvals and has been moving through its regulatory steps for clearance.
1. The Core Trial Design
The CHAMP study utilizes a direct, organ-targeted delivery method designed to attack aggressive liver lesions while simultaneously shielding healthy tissue:
* The Therapeutics: The trial combines 700 mg of leronlimab with 4 months of standard regional Hepatic Artery Infusion Pump (HAIP) chemotherapy.
* The Patient Cohort: The study plans to enroll approximately 36 patients.
* No Pre-Screening Barrier: Crucially, CCR5 positivity is not a gating criterion for patient enrollment. Because the drug is acting broadly on the tissue architecture and protective microenvironment, patients do not need to test positive for a narrow biomarker upfront to qualify.
2. The Dual-Action Endpoints
What makes the CHAMP trial structurally unique is its primary endpoint, which shifts focus to how a therapeutic platform protects an entire organ system:
* The Primary Endpoint (Liver Protection): The trial features a liver biopsy endpoint specifically to assess fibrosis prevention. Chemotherapy delivered directly to the liver via an infusion pump is highly cytotoxic and notorious for causing severe biliary sclerosis and hepatic scarring (fibrosis). By utilizing 700 mg of leronlimab, the trial aims to block the chronic CCL5/CCR5 inflammatory feedback loop that commands hepatic stellate cells to lay down scar tissue.
* The Secondary Endpoint (Anti-Tumor Activity): Alongside organ protection, the study will measure direct radiographic and molecular tumor regression within the liver.
3. Why the 700 mg Dose Matters for the CHAMP Model
By utilizing the higher 700 mg dose, the CHAMP protocol ensures absolute, sustained receptor occupancy directly within the highly dense hepatic environment.
As we mapped out through the Bellomo (THBS1-SPP1 axis) and Qijie Zhao (mechanobiology) frameworks, the liver is the primary geographic battleground where monocytes transform into scar-building, immune-excluding SPP1+ core macrophages. Scurrying through the liver via their CCR5 actin-myosin motors, these cells typically turn chemotherapy-induced cell death into rigid fibrous tissue.
The CHAMP trial is designed to test if leronlimab can enforce mechanical paralysis on these macrophages—preventing both the toxic, pump-induced liver fibrosis and the tumor’s ability to build a defensive structural wall. This allows the high-concentration pump chemotherapy to cleanly destroy the malignant core without destroying the architecture of the liver itself".
2
